A Descriptive Study of the Efficacy and Safety of ONGLYZA (Saxagliptin) Under Conditions of Actual Use in the Philippines.

Trial Profile

A Descriptive Study of the Efficacy and Safety of ONGLYZA (Saxagliptin) Under Conditions of Actual Use in the Philippines.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2013

At a glance

  • Drugs Saxagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ONGLYZA-PMS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 25 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top